PGAM1 (Phosphoglycerate Mutase 1) is a key enzyme in glycolysis, catalyzing the conversion of 3-phosphoglycerate to 2-phosphoglycerate, thus regulating cellular energy metabolism. It is ubiquitously expressed and plays roles beyond glycolysis, including nucleotide synthesis, redox homeostasis, and apoptosis regulation. Dysregulation of PGAM1 is linked to cancers, metabolic disorders, and neurodegenerative diseases. Overexpression of PGAM1 in tumors promotes proliferation, metastasis, and chemoresistance, making it a potential therapeutic target.
PGAM1 antibodies are essential tools for detecting PGAM1 expression and studying its functional mechanisms. These antibodies, often developed in rabbit or mouse hosts, are validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and ELISA. Monoclonal antibodies offer high specificity, while polyclonal antibodies may detect multiple epitopes. Researchers use PGAM1 antibodies to explore its role in disease pathways, evaluate its prognostic value in cancers, and assess therapeutic interventions targeting PGAM1 activity.
Recent studies highlight PGAM1’s interaction with proteins like α-enolase and HSP90. suggesting broader roles in cellular stress responses. Commercial PGAM1 antibodies are widely available, but validation for specific experimental conditions remains critical. Overall, PGAM1 antibodies serve as vital reagents in advancing research on metabolic reprogramming in diseases and developing precision medicine strategies.